BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.223
-0.010 (-4.21%)
At close: Apr 28, 2026, 4:00 PM EDT
0.228
+0.005 (2.15%)
Pre-market: Apr 29, 2026, 5:36 AM EDT
BioRestorative Therapies Revenue
In the year 2025, BioRestorative Therapies had annual revenue of $359.70K, down -10.30%. BioRestorative Therapies had revenue of $19.60K in the quarter ending December 31, 2025, a decrease of -54.73%.
Revenue (ttm)
$359.70K
Revenue Growth
-10.30%
P/S Ratio
15.79
Revenue / Employee
$25,693
Employees
14
Market Cap
5.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 359.70K | -41.30K | -10.30% |
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| CollPlant Biotechnologies | 2.37M |
| XTL Biopharmaceuticals | 968.00K |
| Bio Green Med Solution | 747.00K |
| PMGC Holdings | 590.08K |
| Cardio Diagnostics Holdings | 14.83K |
| Ernexa Therapeutics | 1,000.00 |
BRTX News
- 7 days ago - BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform - GlobeNewsWire
- 21 days ago - BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform - GlobeNewsWire
- 4 weeks ago - BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - GlobeNewsWire
- 7 weeks ago - BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 - GlobeNewsWire
- 2 months ago - BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs - GlobeNewsWire
- 2 months ago - BioRestorative Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 2 months ago - BioRestorative Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire